Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Pfizer
David Fiorentino; Aaron R Mangold; Victoria P Werth; Lisa Christopher-Stine; Alisa Femia; Myron Chu; Amy C M Musiek; Jason C Sluzevich; Lauren V Graham; Anthony P Fernandez; Rohit Aggarwal; Kerri Rieger; Karen M Page; Xingpeng Li; Craig Hyde; Natalie Rath; Abigail Sloan; Barry Oemar; Anindita Banerjee; Mikhail Salganik; Christopher Banfield; Srividya Neelakantan; Jean S Beebe; Michael S Vincent; Elena Peeva; Ruth Ann Vleugels